2 news items
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
IMVT
29 May 24
progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
ARGX
BHVN
IMVT
29 May 24
(NASDAQ:ARGX) Vyvgart (efgartigimod).
The analyst says that the safety profile
- Prev
- 1
- Next